(Q44685336)

5 December 2017

title

Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study (English)

1 reference

5 December 2017

0 references

B W Guess

1

1 reference

5 December 2017

M C Scholz

2

1 reference

5 December 2017

S B Strum

3

1 reference

5 December 2017

R Y Lam

4

1 reference

5 December 2017

H J Johnson

5

1 reference

5 December 2017

R I Jennrich

6

1 reference

5 December 2017

publication date

1 January 2003

1 reference

Prostate Cancer and Prostatic Diseases

5 December 2017

published in

1 reference

5 December 2017

volume

6

1 reference

5 December 2017

issue

4

1 reference

5 December 2017

page(s)

301-304

1 reference

Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

Using splines to detect changes in PSA doubling times.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

Monoclonal antibodies to endogenous galactose-specific tumor cell lectins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

7 January 2021

Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

7 January 2021

Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

7 January 2021

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

7 January 2021

Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

7 January 2021

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500679

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500679

1 reference

5 December 2017

1 reference